I can't answer that question, Mr. Chair, because the nature of the agreements is confidential. Remember, with the U.S. arrangement, in many of its situations, the government actually invested in the companies themselves, so you can't do a dose-per-dose comparison.
On April 16th, 2021. See this statement in context.